Kyntra Bio
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
350 Bay St Ste 100, San Francisco, Calif...Website
www.kyntrabio.comRevenue
$5.9 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Kyntra Bio
Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a U.S. biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It focuses on developing drug candidates for conditions such as anemia, cancer, and other diseases with high clinical impact potential. The company rebranded as Kyntra Bio to reflect a sharpened strategic focus on high-impact therapies.Explore more
Popular SearchesKyntra Bio IncSIC Code 28,283NAICS Code 32,325Show moreKyntra Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kyntra Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Kyntra Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if Kyntra Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Kyntra Bio had a recent Job posting/layoffs
Kyntra Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Kyntra Bio has new funding data
Product Launch: Get notified when Kyntra Bio launches new products
Earning: See what the market has to say on Kyntra Bio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Kyntra Bio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Kyntra Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kyntra Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kyntra Bio.
Most Recent Scoops
Person-Based
Earnings, Finance
Project
Kyntra Bio has announced that its ongoing phase II monotherapy trial for FG-3246 is testing doses of 1.8, 2.4, and 2.7 milligrams per kilogram adjusted body weight with primary G-CSF prophylaxis to mitigate neutropenia, targeting a median radiographic progression-free survival of 10 months or greater as a threshold for commercial competitiveness.
Pharmaceuticals, Clinical Operations
Project
Kyntra Bio has announced that, following interactions with the FDA, the protocol for the phase III study of roxadustat has been finalized with a primary endpoint of 8-week transfusion independence over the first 24 weeks of the trial and key secondary endpoints of 12-, 16-, and 24-week transfusion independence over 48 weeks, as the company continues to explore internal development or a strategic partnership ahead of a Q4 2026 study initiation goal.
Product Development, Pharmaceuticals, Clinical Operations
Earnings
Kyntra Bio has reported USD 95.7 million in cash equivalents, investments, and accounts receivable as of June 30, with the company expecting a cash runway into 2028 to continue investing in its U.S. pipeline opportunities.
Spending/Investment, Business Finance, Finance, Financial Operations
Project
Clinical Operations
Kyntra Bio News & Media
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company’s recent developments.Kyntra Bio to Report Second Quarter 2026 Financial Results
SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) treated with roxadustat will be presented as a poster at the European Hematology Association (EHA) Congress 2026, taking place June 11-14, 2026 in Stockholm, Sweden.Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the first quarter 2026 and provided an update on the company’s recent developments.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kyntra Bio
Sign Up For FreeTo access detailed company insights
Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a U.S. biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It focuses on developing drug candidates for conditions such as anemia, cancer, and other diseases with high clinical impact potential. The company rebranded as Kyntra Bio to... Read More
